1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Novartis AG

Novartis AG

NOVN.SW
Novartis AGCH flagSwiss Exchange
125.10
CHF
-2.82
- -
238.70BMarket Cap
Novartis AG
NOVN.SW
(Swiss Exchange)

Recent

price

125.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
22.56
24.93
21.49
21.6
22.11
20.97
20.79
18.5
19.88
21.25
21.91
19.6
19.93
22.47
25.63
29.23
29.42
Revenue per Share
4.28
3.75
3.83
3.76
4.21
7.4
2.82
3.28
5.44
5.12
3.55
10.71
3.19
7.15
5.92
7.21
7.04
Basic EPS, GAAP
5.18
5.01
4.72
4.01
4.33
3.49
3.61
4.4
5.01
4.96
4.86
5.58
5.5
5.64
6.84
7.86
8.3
Free Cash Flow per Basic Share
1.96
2.25
2.49
2.5
2.81
2.76
2.72
2.77
3
2.9
3.07
3.28
3.44
3.49
3.78
4.03
4.51
Dividend per Share
27.7
27.69
0.41
30.34
30.27
33.86
34.53
33.51
35.85
26.28
25.5
32.05
29.54
24.3
23.47
0.4
19.75
Book Value per Share
2.12
1.69
3.24
6.39
7.3
4.88
5.29
5.32
2.02
0.1
-4.45
1.8
-0.7
-1.67
-3.74
-4.35
-14.61
Tangible Book Value per Share
2,286
2,382
2,418
2,441
2,426
2,403
2,378
2,346
2,319
2,291
2,277
2,243
2,181
2,077
2,018
1,939
1,923
Basic Weighted Avg Shares
51,561
59,375
51,971
52,716
53,634
50,387
49,436
43,404
46,099
48,677
49,898
43,974
43,461
46,660
51,722
56,674
56,578
Sales/Revenue/Turnover
22.35
18.16
22.14
20.83
20.68
17.82
16.72
20.05
18.23
18.67
20.35
22.87
18.28
20.94
28.12
31.13
30.43
Operating Margin (%)
3,419
5,788
4,442
4,405
4,682
5,471
6,043
4,736
5,211
5,826
6,464
5,597
6,705
8,277
6,069
5,325
5,399
Depreciation Expense
9,794
8,940
9,270
9,175
10,210
17,783
6,712
7,703
12,611
11,732
8,072
24,021
6,955
14,850
11,941
13,984
13,534
Net Income, GAAP
14.81
14.05
15.18
13.86
12.59
13.6
14.31
17.61
9.19
20.06
18.29
6.62
15.72
6.04
12.47
14.59
14.38
Effective Tax Rate (%)
18.99
15.06
17.84
17.4
19.04
35.29
13.58
17.75
27.36
24.1
16.18
54.63
16
31.83
23.09
24.67
23.92
Profit Margin (%)
2,027
936
3,953
4,174
10,588
-863
2,722
4,805
5,956
1,240
-3,386
15,510
8,254
4,091
1,012
3,182
-4,767
Working Capital
14,360
13,855
13,781
11,242
13,799
16,327
17,897
23,224
22,470
22,056
27,978
24,523
21,782
20,034
22,934
29,592
39,110
LT Debt
69,769
65,940
69,263
74,472
70,844
77,122
74,891
74,227
78,692
55,551
56,666
67,822
59,423
46,750
44,126
46,549
38,927
Total Equity
11.43
9.94
10.76
10.14
10.26
7.96
7.02
6.98
7
7.25
8.97
9.42
6.96
11.05
16.64
18.61
18.42
Return on Invested Capital (%)
12.42
10.56
18.24
17.08
11.57
18.61
7.01
7.81
12.1
12.12
9.47
24.87
7.8
18.48
16.48
25.99
18.55
Return on Capital (%)
16.21
13.83
27.69
24.44
13.84
22.97
8.21
9.59
15.59
16.37
13.65
36.97
10.2
25.85
24.41
58.12
34.44
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
7,784
5,784
7,888
LT Borrowings
22,598
27,935
37,447
LT Finance Leases
1,640
1,657
1,663
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,919
1,908
1,908
Market Capitalization
247,337
268,832
290,860

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
28,198
30,460
26,607
Cash, Cash Equivalents & STI
9,753
11,533
6,977
Accounts Receivable, Net
8,844
8,937
9,386
Inventories
6,421
6,269
6,286
Total Current Liabilities
32,000
27,278
31,374
Payables & Accruals
7,897
9,517
6,129
ST Debt
7,784
5,784
7,888
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.93%
-2.83%
5.49%
Free Cash Flow
6.52%
6.98%
10.42%
Net Income, GAAP
21.56%
47.51%
17.11%
Sales/Revenue/Turnover
1.5%
2.95%
9.57%
Total Cash Common Dividend
1.72%
2.32%
2.54%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,120
12,872
13,172
13,558
51,722
2025
13,620
14,836
14,358
13,860
56,674
2026
13,524
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.32
1.6
1.58
1.42
5.92
2025
1.83
2.07
- -
1.26
7.21
2026
1.65
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.55
1.19
- -
- -
3.78
2025
2.71
1.28
- -
- -
4.03
2026
3.25
- -
- -
- -
- -
Similar Companies
Sanofi (SNW.DE)
Firebrick Pharma Limited (FRE.AX)
Clarus Therapeutics Holdings, Inc. (CRXTQ)
Merck & Co., Inc. (MRK)
Johnson & Johnson (JNJ)
Bristol-Myers Squibb Company (0R1F.L)
Business
Novartis AG is dedicated to the worldwide discovery, advancement, production, and distribution of pioneering healthcare solutions. The enterprise now operates exclusively as an innovative medicines company, having concluded the full divestiture of its Sandoz generics and biosimilars business in October 2023. Its focused efforts encompass key therapeutic areas, including cardiovascular, renal, and metabolic diseases, immunology, neuroscience, and oncology, striving to address significant global patient needs. Within these domains, Novartis offers a suite of advanced therapies such as Kisqali for breast cancer, Kesimpta for multiple sclerosis, Pluvicto for prostate cancer, and Scemblix for chronic myeloid leukemia, in addition to products like Cosentyx, Leqvio, Fabhalta, and Rhapsido for chronic spontaneous urticaria. The company strategically expands its pipeline through acquisitions and partnerships, evidenced by an increased investment and collaboration with Argo Biopharma on RNA interference therapies for cardiovascular conditions, the acquisition of MorphoSys AG to enhance its oncology offerings, and plans for substantial expansion of its manufacturing footprint in the United States. Novartis AG was established in 1996 and is headquartered in Basel, Switzerland.